CN116064534A - 编码Cas9核酸酶的核酸的饮食控制的表达及其用途 - Google Patents

编码Cas9核酸酶的核酸的饮食控制的表达及其用途 Download PDF

Info

Publication number
CN116064534A
CN116064534A CN202211117939.7A CN202211117939A CN116064534A CN 116064534 A CN116064534 A CN 116064534A CN 202211117939 A CN202211117939 A CN 202211117939A CN 116064534 A CN116064534 A CN 116064534A
Authority
CN
China
Prior art keywords
nucleic acid
cells
expression
cas9
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211117939.7A
Other languages
English (en)
Chinese (zh)
Inventor
P·拉瓦萨德
J·马莱特
C·瑟格拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Institut du Cerveau et de La Moelle Epiniere ICM
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Institut du Cerveau et de La Moelle Epiniere ICM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA, Institut du Cerveau et de La Moelle Epiniere ICM filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CN116064534A publication Critical patent/CN116064534A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
CN202211117939.7A 2016-06-03 2017-06-02 编码Cas9核酸酶的核酸的饮食控制的表达及其用途 Pending CN116064534A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EPEP16172964 2016-06-03
EP16172964 2016-06-03
CN201780045274.4A CN109906271A (zh) 2016-06-03 2017-06-02 编码Cas9核酸酶的核酸的饮食控制的表达及其用途
PCT/EP2017/063549 WO2017207797A1 (en) 2016-06-03 2017-06-02 Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780045274.4A Division CN109906271A (zh) 2016-06-03 2017-06-02 编码Cas9核酸酶的核酸的饮食控制的表达及其用途

Publications (1)

Publication Number Publication Date
CN116064534A true CN116064534A (zh) 2023-05-05

Family

ID=56148119

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211117939.7A Pending CN116064534A (zh) 2016-06-03 2017-06-02 编码Cas9核酸酶的核酸的饮食控制的表达及其用途
CN201780045274.4A Pending CN109906271A (zh) 2016-06-03 2017-06-02 编码Cas9核酸酶的核酸的饮食控制的表达及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780045274.4A Pending CN109906271A (zh) 2016-06-03 2017-06-02 编码Cas9核酸酶的核酸的饮食控制的表达及其用途

Country Status (11)

Country Link
US (2) US20190185832A1 (enExample)
JP (2) JP7436145B2 (enExample)
KR (1) KR102317622B1 (enExample)
CN (2) CN116064534A (enExample)
AU (1) AU2017275769B2 (enExample)
BR (1) BR112018074930A2 (enExample)
CA (1) CA3025591A1 (enExample)
IL (1) IL263291B2 (enExample)
RU (1) RU2771383C2 (enExample)
SG (1) SG11201810772XA (enExample)
WO (1) WO2017207797A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116732043A (zh) * 2023-08-10 2023-09-12 四川省医学科学院·四川省人民医院 一种突变基因及其白内障筛查的用途与白内障筛查试剂盒

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019314475A1 (en) * 2018-08-01 2021-02-18 The Regents Of The University Of Colorado A Body Corporate Programmable designer therapeutic fusogenic secreted gectosome vesicles for macromolecule delivery and genome modification
CN115820654A (zh) * 2019-08-30 2023-03-21 深圳华大基因股份有限公司 Loxhd1基因突变体及其应用
CN114058689B (zh) * 2020-07-30 2024-08-20 南京市妇幼保健院 一种基因突变检测试剂盒及其应用
AU2023304674A1 (en) * 2022-07-05 2025-01-16 Centre Hospitalier Universitaire De Clermont-Fd Controlled expression of a transgene in human t or nk cells for use in cellular immunotherapy
WO2024100176A1 (en) * 2022-11-10 2024-05-16 Nutritheragene Controlled gene therapy of ocular diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2982277B1 (fr) * 2011-11-08 2015-08-21 Agronomique Inst Nat Rech Cassette d'expression inductible et ses utilisations
PT3363902T (pt) * 2012-12-06 2019-12-19 Sigma Aldrich Co Llc Modificação e regulação de genoma baseadas em crispr
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
BR112016013201B1 (pt) * 2013-12-12 2023-01-31 The Broad Institute, Inc. Uso de uma composição compreendendo um sistema crispr-cas no tratamento de uma doença genética ocular
EP3540051B1 (en) * 2013-12-12 2022-08-17 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hsv and viral diseases and disorders.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116732043A (zh) * 2023-08-10 2023-09-12 四川省医学科学院·四川省人民医院 一种突变基因及其白内障筛查的用途与白内障筛查试剂盒
CN116732043B (zh) * 2023-08-10 2023-10-17 四川省医学科学院·四川省人民医院 一种突变基因及其白内障筛查的用途与白内障筛查试剂盒

Also Published As

Publication number Publication date
AU2017275769A1 (en) 2018-12-20
IL263291A (en) 2018-12-31
RU2018142174A3 (enExample) 2020-09-30
JP2022133441A (ja) 2022-09-13
CA3025591A1 (en) 2017-12-07
US20190185832A1 (en) 2019-06-20
AU2017275769B2 (en) 2023-04-13
JP2019517262A (ja) 2019-06-24
BR112018074930A2 (pt) 2019-03-12
KR20190031230A (ko) 2019-03-25
IL263291B1 (en) 2023-03-01
WO2017207797A1 (en) 2017-12-07
RU2018142174A (ru) 2020-07-10
KR102317622B1 (ko) 2021-10-26
US20230313161A1 (en) 2023-10-05
CN109906271A (zh) 2019-06-18
RU2771383C2 (ru) 2022-05-04
IL263291B2 (en) 2023-07-01
SG11201810772XA (en) 2018-12-28
JP7436145B2 (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
US20230313161A1 (en) Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof
KR101513254B1 (ko) 트랜스펙션 및 면역자극을 위한 ｒｎａ 및 양이온성 펩타이드의 복합체
ES2937245T3 (es) ARN que contiene nucleósidos modificados y métodos de uso del mismo
CN107949424B (zh) Tat诱导的基于crispr/核酸内切酶的基因编辑
ES2769129T3 (es) Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células
CN102256999B (zh) 向白细胞的有效转运
US20180073018A1 (en) Compositions and methods for specific reactivation of hiv latent reservoir
WO2017153936A1 (en) Chemically modified messenger rna's
JPWO2020014209A5 (enExample)
CN107530399A (zh) 治疗分子在体外和体内的有效递送
JP6875500B2 (ja) Ｃａｓ９タンパク質およびガイドＲＮＡを含む眼疾患治療用薬学組成物
CN107406854A (zh) Rna指导的人类jc病毒和其他多瘤病毒的根除
Neschadim et al. Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer
Feng et al. Generation of anti‐mastitis gene‐edited dairy goats with enhancing lysozyme expression by inflammatory regulatory sequence using ISDra2‐TnpB system
US20250057780A1 (en) Nanoparticles and methods of production for the encapsulation of nucleic acids
US20240401047A1 (en) Trem compositions and methods of use
EP3464574A1 (en) Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof
Aneja et al. Optimization of Streptomyces bacteriophage ϕC31 integrase system to prevent post integrative gene silencing in pulmonary type II cells
Lopes et al. Gene Editing for ATXN3 Inactivation in Machado-Joseph disease: CRISPR-Cas9 as a Therapeutic Alternative to TALEN-Induced Toxicity
TW202507003A (zh) Ｔｒｅｍ組合物及使用方法
KR20250171374A (ko) Trem 조성물 및 사용 방법
US20090221468A1 (en) Autonomously Replicating KSHV CIS-Acting Elements
Xia CRISPR-cas9 and TALEN Mediated Gene Editing for Treating Cystic Fibrosis
HK40000290A (en) Excision of retroviral nucleic acid sequences

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination